Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018
LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received…